Highlights
NASDAQ: RXDX       Prometheus Biosciences Inc
Last Price Today's Change   Day's Range   Trading Volume
108.68   +0.25 (0.23%)  106.99 - 110.00  320,071

Overview

 
Avg Volume (4 weeks):0
52 Weeks Range:21.50 - 117.13
52 Weeks Price Volatility (%):
91.16%
Average Price Target:-

Headlines



No recent Headlines for this stock.


Business Background

Ignyta, Inc. is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company's pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106. Entrectinib is an orally bioavailable, central nervous system (CNS)-active, small molecule tyrosine kinase inhibitor directed to the tropomyosin receptor kinase (TRK) family of tyrosine kinase receptors (TRKA, TRKB and TRKC), ROS1 and anaplastic lymphoma kinase (ALK) proteins. RXDX-105 is an orally bioavailable, vascular endothelial growth factor receptor (VEGFR)-sparing, small molecule tyrosine kinase inhibitor of rearranged during transfection (RET). Taladegib is an orally bioavailable, small molecule hedgehog/smoothened antagonist. RXDX-106 is a pseudo-irreversible, small molecule inhibitor of TYRO3, AXL and MER (collectively TAM), and c-MET.

  Be the first to like this.
 


APPS
I3 Messenger
Individual or Group chat with anyone on I3investor
 
 

4414  5693  1135  752 

ActiveGainersLosers
Top 10 Active Counters
 NameLastChange 
 MULN 0.408+0.027 
 TQQQ 25.52-1.39 
 TSLA 189.98+1.71 
 SQQQ 34.67+1.66 
 F 13.23-1.09 
 XELA 0.06-0.004 
 AAPL 154.50+3.68 
 AMZN 103.39-9.52 
 ISBC 13.87-0.35 
 SOXL 16.93-0.99